文献速递肝病消化道肿瘤与早癌

肝细胞癌免疫治疗:扩大肝移植可及性的下一项进展

Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation.
PubMed 文献 · J Hepatol · 2024-06-05

免疫治疗已革新晚期肝细胞癌治疗,多项III期试验在早中期肝细胞癌联合手术或局部治疗中报告阳性结果。本综述讨论免疫治疗用于肝移植前人群的作用,分析其可能改善降期成功率和肿瘤控制,同时带来免疫相关毒性和移植后急性排斥反应等风险。

要点

  • 免疫治疗在早中期肝细胞癌联合手术或局部治疗的III期试验中已报告阳性结果。
  • 移植前免疫治疗可能改善降期成功率和肿瘤控制,但存在免疫相关毒性和急性排斥风险。
  • 本综述探讨免疫治疗在选定高危患者肝移植前新辅助治疗中的应用。

核心结论

  • 免疫治疗在移植前人群的最终目标是有效扩大肝移植可及性,同时保持移植前和移植后结局。

研究设计与样本

  • 本综述讨论支持联合免疫治疗的机制,总结主要免疫治疗试验的关键近期临床数据,并探讨免疫治疗在选定高危患者肝移植前新辅助治疗中的应用。

主要发现

  • 免疫治疗已革新晚期肝细胞癌的治疗。
  • 多项早中期肝细胞癌免疫治疗联合手术或局部治疗的III期试验近期报告阳性结果,其他III期试验正在进行中。
  • 在移植前患者中,免疫治疗可能改善降期成功率和肿瘤控制,代价是免疫相关毒性等免疫学风险,以及移植后急性排斥反应的可能性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunotherapy has revolutionised the treatment of advanced hepatocellular carcinoma (HCC). In addition, several phase III trials of immunotherapy in combination with surgical or locoregional therapies for early-to intermediate-stage HCC have recently reported positive results, and other phase III trials in the same patient population are currently in progress. As the application of immunotherapy is shifting to include patients with earlier stages of HCC, one looming question now emerges: What is the role of immunotherapy in the pre-liver transplant population? Liver transplantation is a potentially curative therapy for HCC and confers the additional advantage of restoring a normal, healthy liver. In pre-transplant patients, immunotherapy may improve downstaging success and tumour control at the cost of some immunologic risks. These include immune-related toxicities, which are particularly relevant in a uniquely vulnerable population with chronic liver disease, and the possibility of acute rejection after transplantation. Ultimately, the goal of immunotherapy in this population will be to effectively expand access to liver transplantation while preserving pre- and post-transplant outcomes. In this review, we discuss the mechanisms supporting combination immunotherapy, summarise key recent clinical data from major immunotherapy trials, and explore how immunotherapy can be applied in the neoadjuvant setting prior to liver transplantation in selected high-risk patients.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Li M, Bhoori S, Mehta N, et al. Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation. J Hepatol. 2024. PMID: 38848767. doi:10.1016/j.jhep.2024.05.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。